News | Prostate Cancer | September 26, 2016

Extremely Hypofractionated Radiotherapy Shows Promising Toxicity Results for Intermediate-Risk Prostate Cancer

Large Scandinavian trial finds comparable side effects at two years following 42.7 Gy delivered in seven fractions compared to 78 Gy delivered in 39 treatments

prostate cancer, hypofractionated radiation therapy, HYPO-RT-PC trial, ASTRO 2016

September 26, 2016 — For men with intermediate-risk prostate cancer, side effects at two years following radiation therapy (RT) were comparable for extremely-hypofractionated treatment and conventional treatment, according to research presented at the 58th Annual Meeting of the American Society for Radiation Oncology (ASTRO).

The extremely-hypofractionated treatment was delivered in seven fractions across two and a half weeks, while conventional treatment was delivered 39 fractions across eight weeks.

The HYPO-RT-PC trial — a randomized, multi-institutional phase III trial in Scandinavia — was designed to assess outcomes from highly accelerated extreme hypofractionation, which is delivered in smaller number of high doses — seven fractions of 6.1 Gy each in this study.

“Randomized trials have confirmed the value of radiation dose escalation for prostate tumors, and the potential benefits of larger radiation doses in fewer fractions are expected to increase the therapeutic efficacy for men with prostate cancer,” said Anders Widmark, M.D., a professor of radiation sciences at Umeå University in Umeå, Sweden and lead author of the study. “Most of the existing data on hypofractionation, however, draws on cases of moderately accelerated radiation treatment of the prostate, in contrast to our study with more extreme hypofractionation. Our trial shows that patients experience similar side effects at two years with highly accelerated extremely hypofractionation.”

Twelve hundred men with intermediate-risk prostate cancer were enrolled in the HYPO-RT-PC non-inferiority trial between 2005 and 2015. Eligible patients presented with tumor stages of T1c to T3a, prostate-specific androgen (PSA) levels of 20 or below, and one or two of three risk factors: stage T3a, a Gleason tumor score of seven or higher, or a PSA level greater than 10.

Patients were randomized to one of two treatment arms: The conventional fractionation group (CF) received 78 Gy of image-guided RT to the prostate in 39 treatments of 2 Gy each over eight weeks, and the extreme hypofractionation group (E-HF) received 42.7 Gy in seven treatments of 6.1 Gy each over two and a half weeks. Most patients (80 percent) received three-dimensional conformal RT (3DCRT), and the remaining patients received volumetric arc therapy (VMAT). Androgen deprivation therapy was not allowed among study participants.

Primary outcomes included physician-reported side effects measured via a modified RTOG scale and patient-reported outcomes of urinary, bowel and sexual function side effects measured with the Prostate Cancer Symptom Scale (PCSS) questionnaire. Side effects were measured prior to RT start (baseline), at the end of RT, and at three, six, 12, 18 and 24 months following completion of RT. Median follow-up time from randomization for the entire patient population was 4.2 years, and findings reflect the 866 patients who reached two-year follow-up at the time of reporting in May 2016.

Men who received extremely hypofractionated RT in seven treatments experienced similar side effects two years following treatment as those who received conventional RT in 39 treatments. Rates of physician-reported grade 2+ toxicities at two years following treatment did not differ significantly between treatment arms. Urinary side effects were reported for 5.4 percent of E-HF patients and 4.6 of CF patients (p = 0.59). Bowel side effects were reported for 2.2 percent of E-HF patients and 3.7 percent of CF patients (p = 0.20). Impotence at two years post-treatment was reported in 34 percent of both groups, compared to 16 percent among all participants at baseline. Patient-reported outcomes at two years following treatment also did not differ significantly between treatment groups for overall bother from urinary (p = 0.17), bowel (p = 0.12) or sexual function (p = 0.71) symptoms.

Some modest but statistically significant differences emerged between the accelerated and conventional treatment arms in shorter-term bowel and urinary side effects. Acute urinary toxicity immediately following treatment was similar for both treatment groups (27.6 percent for E-HF vs. 22.8 percent for C-HF, p = 0.11), although acute bowel toxicity at the end of RT was higher for the accelerated E-HF treatment than for CF (9.4 vs. 5.3 percent; p = 0.023). Patient-reported bowel function at the end of RT was also significantly worse following E-HF than following CF for seven of 10 symptoms assessed, although these differences dissipated at three and six months follow-up. At one year post-treatment, patient-reported urinary function was significantly worse among E-HF patients for four of the 14 symptoms measured.

“The trial was designed to have equal late toxicity, so although there were some differences in shorter-term side effects, the results for long-term toxicity were precisely what we hoped to find,” said Widmark. “Our plan moving forward is to analyze primary endpoint data and present updated toxicity results approximately one year from now.”

For more information: www.astro.org

Related Content

Videos | Radiation Therapy | February 21, 2019
ITN Associate Editor Jeff Zagoudis speaks with Christy Kesslering, M.D., medical director of radiation oncology at th
FDA Clears Advancements for Viewray MRIdian Radiation Therapy System
Technology | Image Guided Radiation Therapy (IGRT) | February 21, 2019
February 21, 2019 — ViewRay Inc. received 510(k) clearance from the U.S.
Videos | Radiation Therapy | February 20, 2019
ITN Associate Editor Jeff Zagoudis speaks with Vinai Gondi, M.D., director of research and CNS neuro-oncology at the
Study Unveils Blueprint for Treating Radiation-Resistant Brain Tumor

NIH-funded researchers showed how gliomas may be treated with radiation and drugs that block DNA repair. Image courtesy of Castro lab, Michigan Medicine, Ann Arbor

 

News | Radiation Therapy | February 19, 2019
February 19, 2019 — Researchers at the University of Michigan recently searched for new brain tumor treatments by exp
Amazon Comprehend Medical Brings Medical Language Processing to Healthcare
News | Artificial Intelligence | February 15, 2019
Amazon recently announced Amazon Comprehend Medical, a new HIPAA-eligible machine learning service that allows...
Videos | Radiation Therapy | February 15, 2019
ITN Associate Editor Jeff Zagoudis speaks with Vinai Gondi, M.D., director of research and CNS neuro-oncology at the
New Targeted Therapy for Recurrent Brain Tumors Implanted for First Time
News | Radiation Therapy | February 15, 2019
University of Minnesota Health (M Health) is the first in the United States to begin offering GammaTile Therapy, a new...
Micro-Ultrasound and Artificial Intelligence Combining to Detect Prostate Cancer
News | Prostate Cancer | February 12, 2019
Cambridge Consultants has partnered with Exact Imaging, makers of the ExactVu micro-ultrasound platform, as the two...
Canon Adds Radiation Therapy Package to Aquilion Prime, Lightning CT Systems
News | Computed Tomography (CT) | February 11, 2019
In the patient-centric world of radiation oncology, it is critical that computed tomography (CT) simulation is...
Elekta Unity MR-Linac Earns FDA Clearance
Technology | Image Guided Radiation Therapy (IGRT) | February 07, 2019
The Elekta Unity magnetic resonance radiation therapy (MR/RT) system recently received 510(k) premarket notification...